Sarepta Therapeutics, Inc. Financials

Market Capitalization $1.79 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	19.98
Forward PE	1.59
Price to Sales TTM	$0.80
Price to Book MRQ	$1.57
Enterprise to Revenue	1.13
Enterprise to EBITDA	-32.13

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-11.12%
Operating Margin	-40.33%
Return on Assets TTM	-2.19%
Return on Equity TTM	-23.61%

Income Statement

Revenue TTM	$2,233,370,880
Revenue per Share TTM	$23.28
Quarterly Revenue Growth	80.20%
Gross Profit TTM	$449,692,992
EBITDA	$324,727,000
Net Income to Common TTM	$-248,388,000
Diluted EPS TTM	$-2.64
Quarterly Earnings Growth YoY	80.15%

Balance Sheet

Total Cash MRQ	$522,761,984
Total Cash per Share MRQ	$5.32
Total Debt MRQ	$
Total Debt to Equity MRQ	118.73
Current Ratio MRQ	4.02
Book Value per Share MRQ	$11.63

Cash Flow

Operating Cash Flow TTM	$-547,148,032
Levered Free Cash Flow TTM	$-741,256,256

SRPT Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	96,900,496
Float Shares	93,857,514
Avg 10 Volume	6,628,289
Avg 30 Volume	None
Shares Short	9,885,949
Short Ratio	2.61
Short % of Shares	11.79%
% Held by Insiders	4.42%
% Held by Institutions	96.33%

Stock Price Summary

Beta	0.60
Fifty Two Week Low	$16.88
Fifty Two Week High	$154.90
Fifty Two Week Change	-731.85%
Day 50 MA	$38.26
Day 200 MA	$91.72

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2012-07-12